Epaminurad
CAS No. : 1198153-15-9
(Synonyms: UR-1102; URC-102)
| Size | Price | Stock |
|---|---|---|
| 5mg | $300 | In-stock |
| 10mg | $480 | In-stock |
| 25mg | $960 | In-stock |
| 50mg | $1540 | In-stock |
| 100 mg | Get quote | |
| 200 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-111345 |
| M.Wt: | 414.05 |
| Formula: | C14H10Br2N2O3 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a Ki of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research[1].
IC50 & Target:Ki: 0.057 ± 0.036 μM (URAT1), 2.4 ± 0.2 μM (OAT3), 7.2 ± 0.8 μM (OAT1)[1].
In Vitro: UR-1102 (0-12 μM) inhibits urate and PAH (p-aminohippuric acid) uptake by HEK293 cells transiently expressing URAT1, OAT1, or OAT3[1].
In Vivo: Epaminurad (0-30 mg/kg, Orally, once a day for 3 consecutive days) shows uricosuric and urate-lowering effects[1].
Epaminurad (3-30 mg/kg, Orally, once) shows a good pharmacokinetic profile, increases the fractional excretion of urinary uric acid, and reduces plasma uric acid more effectively[1].
Pharmacokinetic Parameters of Epaminurad (UR-1102) in tufted capuchin monkeys[1].
| Group | 3 mg/kg | 10 mg/kg | 30 mg/kg |
| Cmax (μg/mL) | 8.96 ± 1.74 | 42.4 ± 12.8 | 92.9 ± 21.0 |
| Tmax (h) | 0.6 ± 0.2 | 0.5 ± 0.0 | 0.8 ± 0.3 |
| T1/2 (h) | 4.7 ± 0.9 | 4.2 ± 1.1 | 3.3 ± 0.8 |
| AUC0-inf (mg*h/mL) | 26.2 ± 8.1 | 108 ± 51 | 257 ± 60 |